Disclosed herein are a solid Form of a TYK2 inhibitor N-(5-(2,2-dimethyl-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)-4-((6-(methylsulfonyl)-4-(tetrahydro-2H-pyran-4-yl)pyridin-2-yl)amino)pyridin-2-yl)acetamide per se and the pharmaceutically acceptable salts of the TYK2 inhibitor or crystalline Forms of the salts, pharmaceutical compositions comprising the crystalline Form or the salts or the salts in crystalline Forms, the processes for preparing the crystalline Form or the salts or the salts in crystalline Forms, and methods of use therefor.

Crystalline forms of 5-(4-cyclopropyl-1H-imidazol-1-yl)-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-2-fluoro-4-methylbenzamide(Compound I) were prepared and characterized in the solid state: ##STR00001## Also provided are processes of manufacture and methods of using the crystalline forms.

Crystalline forms of 5-(4-cyclopropyl-1H-imidazol-1-yl)-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-2-fluoro-4-methylbenzamide(Compound I) were prepared and characterized in the solid state: ##STR00001## Also provided are processes of manufacture and methods of using the crystalline forms.

The present invention relates to maleate salt forms of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide, methods of preparing crystalline maleate salt forms, the associated compounds, and pharmaceutical compositions containing the same. The maleate salts are useful in treating cancers, particularly those affected by kinases of the epidermal growth factor receptor family.

The present invention relates to maleate salt forms of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide, methods of preparing crystalline maleate salt forms, the associated compounds, and pharmaceutical compositions containing the same. The maleate salts are useful in treating cancers, particularly those affected by kinases of the epidermal growth factor receptor family.

The invention concerns compounds of Formula (I) ##STR00001##
or pharmaceutically-acceptable salts thereof, wherein R.sup.1 to R.sup.5 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.

The invention concerns compounds of Formula (I) ##STR00001##
or pharmaceutically-acceptable salts thereof, wherein R.sup.1 to R.sup.5 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.

The disclosure provides solid forms, e.g. salts and crystalline forms thereof, of the compound of Formula I and uses thereof. Also provided are the methods of making the solid forms, as well as pharmaceutical formulations and kits comprising the solid forms.

The disclosure provides solid forms, e.g. salts and crystalline forms thereof, of the compound of Formula I and uses thereof. Also provided are the methods of making the solid forms, as well as pharmaceutical formulations and kits comprising the solid forms.

A salt crystal form and a free base crystal form of a kinase inhibitor are provided. Specifically, the kinase inhibitor can be a salt crystal form formed by a compound as shown in formula I and different acids, and a free base crystal form thereof.

##STR00001##